T-Mobile's Prism: N...
Health Care: Drugs
United Therapeutics Corporation (UTHR: NASDAQ)
$42.67 0.15 | 0.35%
05/24/12 - 04:00 PM ET
807.56K / 714.80K
Vol / Avg. Vol:42.67 / 42.52
Open / Prev. Close:42.21 - 43.00
Today's Range:36.55 - 65.81
52 Wk Range:-10.01%
Performance YTD:TheStreet Rating:
Portfolios with UTHR
- Portfolio NameUser Type
- Contributor8 Health Care Stocks Inside...
- ContributorStocks With Big Insider Buy...
- Contributor5 Biotech Stocks for 2012
- Contributor5 Low PEG / Low Beta Stocks
- Contributor13 Biotech Stocks Bought an...
- Contributor8 Health Care Stocks to Buy
- ContributorTheStreet Ratings Top-Rated...
- UserPART 6 JPMorgan 28th Annual...
- ContributorHealth Stock Short Squeezes
- ContributorFast Money's Biotech Takeov...
Latest UTHR Headlines from TheStreet
- United Therapeutics' CEO Discusses Q1 2012 Results - Earnings Call Transcript 04.26.12 | 07:04 pm
- United Therapeutics' CEO Discusses Q4 2011 Results - Earnings Call Transcript 02.14.12 | 11:02 am
- United Therapeutics Gets Upgrade on Revenue Growth 01.12.12 | 08:01 am
- United Therapeutics Corporation Stock Upgraded (UTHR) 01.12.12 | 05:01 am
- 8 Health Care Stocks Insiders Are Bullish on 12.28.11 | 04:12 pm
- 5 Stocks Insiders Love Right Now 12.15.11 | 12:12 pm
- 5 Biotech Stocks for 2012 12.09.11 | 09:12 am
- 5 Low-Risk Stocks to Buy for 2012 12.01.11 | 06:12 am
- United Therapeutics Corporation (UTHR): Today's Featured Health Care Loser 11.10.11 | 04:11 pm
- United Therapeutics Corporation (UTHR): Today's Featured Drugs Loser 11.01.11 | 05:11 pm
Press Releases for UTHR
- United Therapeutics Files Lawsuit Against Sandoz For Infringement Of Remodulin Patents - PR Newswire 03.15.12 | 07:03 am
- Oral Treprostinil New Drug Application Accepted By FDA For Review - PR Newswire 02.21.12 | 07:02 am
- United Therapeutics Corporation To Announce Fourth Quarter And Annual 2011 Financial Results Before Market Open On Tuesday, February 14, 2012 - PR Newswire 02.07.12 | 07:02 am
- United Therapeutics Receives Paragraph IV Notice Letter For Remodulin - PR Newswire 02.06.12 | 07:02 am
- Intravenous Remodulin Approved For The Treatment Of Pulmonary Arterial Hypertension In Most Of The European Union - PR Newswire 12.27.11 | 07:12 am
- United Therapeutics Corporation To Announce Third Quarter 2011 Financial Results Before Market Open On Thursday, October 27, 2011 - PR Newswire 10.20.11 | 07:10 am
- United Therapeutics Prices Private Offering Of Convertible Senior Notes And Announces Concurrent Exercise Of Overallotment Option - PR Newswire 10.12.11 | 07:10 am
- United Therapeutics Announces Proposed Private Offering Of $210 Million Of Convertible Senior Notes And Authorization Of Stock Repurchase Program - PR Newswire 10.11.11 | 07:10 am
- United Therapeutics Subsidiary Enters Into Contract With National Institutes Of Health For Award Of Up To $45 Million To Support Glycobiology Antiviral Program - PR Newswire 10.10.11 | 07:10 am
- FREEDOM-C(2) Trial Of Oral Treprostinil In Pulmonary Arterial Hypertension Does Not Meet Primary Endpoint - PR Newswire 08.24.11 | 05:08 am
Partner Headlines for UTHR
- UPDATE: Ladenburg Thalmann Lowers United Therapeutics' PT - Benzinga 04.30.12 | 09:04 am
- UPDATE: Canaccord Downgrades United Therapeutics; Lowers PT - Benzinga 04.27.12 | 10:04 am
- Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics - Press Releases - Zacks 04.27.12 | 09:04 am
- Neutral on United Therapeutics - Analyst Blog - Zacks 03.30.12 | 07:03 pm
- UTHR Files Suit vs. Sandoz - Analyst Blog - Zacks 03.16.12 | 07:03 pm
- Action Date for UTHR Candidate - Analyst Blog - Zacks 02.24.12 | 07:02 pm
- A Baker's Dozen Of Top Value-Stocks For 2012: Part III - Seeking Alpha 02.03.12 | 08:02 am
- Activist Hedge Fund Accipiter Capital's Top Stock Picks - Seeking Alpha 11.29.11 | 09:11 am
- Zacks Releases Four Powerful ''Buy'' Stocks: United Therapeutics, Monsanto, Universal and Genesco - Press Releases - Zacks 11.29.11 | 09:11 am
- United Therapeutics Corp - Aggressive Growth - Zacks 11.29.11 | 01:11 am
